gastrin/cck-b

CCK-B Receptor Antagonist 2 is a potent and orally active antagonist of Gastrin CCK-B (IC50: 0.43 nM). It also inhibits gastrin CCK-A activity (IC50: 1.82 μM).

Sograzepide (Netazepide) 是一种具有口服活性选择性和高效性的 Gastrin CCK-B 拮抗剂，抑制 Gastrin CCK-A 活性，抑制 1 型胃神经内分泌肿瘤中 Pappalysin 2 的表达，可诱导 1 型胃神经内分泌肿瘤消退。

YM022 is a highly effective and selective gastrin cholecystokinin (CCK)-B receptor antagonist. YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively.

L-365260 是一种可口服且具有选择性和高效性的非肽胃泌素和脑胆囊收缩素受体 (CCK-B) 拮抗剂。L-365260 抑制 CCK-8S 诱导的 [Ca2+]i 增加，可阻断应激引起的内脏超敏反应，可阻断 CCK-4 的抗探索作用，可用于研究神经系统Ojibwa和内分泌疾病。

DA-3934 has a high affinity for gastrin/CCK-B receptors and high selectivity over CCK-A receptors. DA-3934 and its methyl ester derivative inhibited pentagastrin-induced gastric acid secretion in rats in a dose-dependent manner.

Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat. Gastrin (cholecystokinin type B (CCK-B)) receptor antagonists may help to elucidate the physiological role o

L-365260 hemihydrate 是选择性的、具有口服活性的非肽胃泌素和脑胆囊收缩素受体 (CCK-B) 拮抗剂，Kis 值分别为 1.9 nM 和 2.0 nM。L-365260 hemihydrate 以竞争性方式与豚鼠胃泌素和脑 CCK 受体相互作用。

[Leu15]-Gastrin I human acetate(39024-57-2 Free base) 是一种肽，通过 G 蛋白偶联受体，即胆囊收缩素 (CCK) 或 CCK-B 受体 (CCK-BR) 发挥作用。